GlassScriptPhysician profile
Clinton Mcentyre
NPI 1518040005
$17,250.52
in general payments reported to CMS, 2019-2025
48 companies · $2,132 in 2025
The $2,132 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,442 · 2020: $1,983 · 2021: $2,360 · 2022: $2,745 · 2023: $2,978 · 2024: $2,611 · 2025: $2,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,720.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,113.55 | 2019-2025 | |
| Pfizer INC. | $1,885.44 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,775.07 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,584.10 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,457.97 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,238.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $595.24 | 2019-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $552.89 | 2019-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $513.75 | 2019-2023 | Xarelto |
| Corium, LLC | $498.73 | 2023-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $488.35 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.37 | 2019-2025 | Jardiance, Ofev |
| Daiichi Sankyo INC. | $380.95 | 2019-2023 | Injectafer |
| Allergan, INC. | $345.26 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $333.53 | 2022-2023 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clinton Mcentyre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.